IL141850A - High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-3n-20-yn-3-one - Google Patents

High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-3n-20-yn-3-one

Info

Publication number
IL141850A
IL141850A IL14185099A IL14185099A IL141850A IL 141850 A IL141850 A IL 141850A IL 14185099 A IL14185099 A IL 14185099A IL 14185099 A IL14185099 A IL 14185099A IL 141850 A IL141850 A IL 141850A
Authority
IL
Israel
Prior art keywords
7alpha
17alpha
pregn
hydroxy
methyl
Prior art date
Application number
IL14185099A
Other languages
English (en)
Other versions
IL141850A0 (en
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL141850(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of IL141850A0 publication Critical patent/IL141850A0/he
Publication of IL141850A publication Critical patent/IL141850A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
IL14185099A 1998-10-16 1999-10-11 High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-3n-20-yn-3-one IL141850A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203460 1998-10-16
PCT/EP1999/007768 WO2000023460A1 (en) 1998-10-16 1999-10-11 HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE

Publications (2)

Publication Number Publication Date
IL141850A0 IL141850A0 (en) 2002-03-10
IL141850A true IL141850A (en) 2005-11-20

Family

ID=8234220

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14185099A IL141850A (en) 1998-10-16 1999-10-11 High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-3n-20-yn-3-one

Country Status (30)

Country Link
US (3) US6969708B1 (xx)
EP (2) EP1275379A3 (xx)
JP (1) JP2002527525A (xx)
KR (3) KR20050003358A (xx)
CN (2) CN100378116C (xx)
AR (1) AR020832A1 (xx)
AT (1) ATE239032T1 (xx)
AU (1) AU763232B2 (xx)
BR (1) BR9914441A (xx)
CA (1) CA2344686C (xx)
CO (1) CO5160271A1 (xx)
CZ (1) CZ298703B6 (xx)
DE (1) DE69907495T2 (xx)
DK (1) DK1121375T3 (xx)
ES (1) ES2197677T3 (xx)
HK (1) HK1039620B (xx)
HU (1) HUP0104206A3 (xx)
ID (1) ID28463A (xx)
IL (1) IL141850A (xx)
NO (1) NO317427B1 (xx)
NZ (1) NZ510501A (xx)
PE (1) PE20001377A1 (xx)
PL (1) PL197870B1 (xx)
PT (1) PT1121375E (xx)
RU (1) RU2220975C2 (xx)
SK (1) SK284569B6 (xx)
TR (2) TR200504091T2 (xx)
TW (2) TW200403251A (xx)
WO (1) WO2000023460A1 (xx)
ZA (1) ZA200101952B (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356465A1 (en) * 2002-10-04 2004-04-05 ANPHARM Przedsiębiorstwo Farmaceutyczne S.A. METHOD OF MANUFACTURE OF 17beta-HYDROXY-7alpha-METHYL-19-NOR-17alpha-PREGN-5(10)-ENE-20-YNE-3-ONE
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
LT2662380T (lt) 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
DK1848727T3 (da) 2005-02-01 2015-07-20 Hoffmann La Roche Ibandronat polymorf b
WO2006125453A1 (en) * 2005-05-23 2006-11-30 Newchem S.P.A. Process for the preparation of pure crystalline tibolone
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
ITMI20130120A1 (it) * 2013-01-25 2014-07-26 Ind Chimica Srl Processo per la preparazione in forma cristallina di tibolone, (7alfa,17alfa)-17-idrossi-7-metil-19-norpregn-5(10)-en-20-in-3-one
US20220046948A1 (en) * 2018-12-17 2022-02-17 Aimmune Therapeutics, Inc. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN114409717B (zh) * 2021-12-17 2023-03-17 湖南科益新生物医药有限公司 替勃龙中间体醚化物和替勃龙的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE665514A (xx) * 1964-06-16
CH488682A (de) * 1965-07-30 1970-04-15 Ciba Geigy Verfahren zur Herstellung von 4,9,11-Trienen der 19-Nor-androstanreihe
NL146838B (nl) * 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
US3515719A (en) * 1967-03-15 1970-06-02 Upjohn Co 7-methyl-6,19-epoxy steroids of the androstane series
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
JPH03503414A (ja) * 1988-03-25 1991-08-01 アクゾ・エヌ・ヴエー フッ化物塩を含有する医薬製剤
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
ES2134313T3 (es) * 1993-03-05 1999-10-01 Akzo Nobel Nv Utilizacion de derivados de pregnano para el tratamiento de tumores.
CA2159419C (en) 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
TW448049B (en) * 1997-03-05 2001-08-01 Akzo Nobel Nv Use of a 7Α-methyl-17Α-ethynyl-estrane derivative for the treatment of atherosclerosis
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable

Also Published As

Publication number Publication date
EP1275379A2 (en) 2003-01-15
KR20010080133A (ko) 2001-08-22
DK1121375T3 (da) 2003-08-04
TR200504091T2 (tr) 2006-05-22
ATE239032T1 (de) 2003-05-15
US20040248870A1 (en) 2004-12-09
PL347264A1 (en) 2002-03-25
IL141850A0 (en) 2002-03-10
KR100635018B1 (ko) 2006-10-17
HUP0104206A3 (en) 2002-06-28
PT1121375E (pt) 2003-07-31
CZ2001976A3 (cs) 2001-08-15
CN100378116C (zh) 2008-04-02
NO20011664D0 (no) 2001-04-03
TR200101083T2 (tr) 2001-08-21
KR20050003358A (ko) 2005-01-10
WO2000023460A1 (en) 2000-04-27
AR020832A1 (es) 2002-05-29
CN1322210A (zh) 2001-11-14
HUP0104206A2 (hu) 2002-04-29
PL197870B1 (pl) 2008-05-30
HK1039620A1 (en) 2002-05-03
TW577893B (en) 2004-03-01
CN1769293A (zh) 2006-05-10
AU763232B2 (en) 2003-07-17
US6969708B1 (en) 2005-11-29
NO317427B1 (no) 2004-10-25
PE20001377A1 (es) 2000-12-09
CO5160271A1 (es) 2002-05-30
SK284569B6 (sk) 2005-06-02
ZA200101952B (en) 2002-06-10
BR9914441A (pt) 2001-06-26
DE69907495D1 (de) 2003-06-05
NZ510501A (en) 2003-10-31
ID28463A (id) 2001-05-24
AU6202999A (en) 2000-05-08
EP1121375A1 (en) 2001-08-08
CN100432093C (zh) 2008-11-12
TW200403251A (en) 2004-03-01
EP1275379A3 (en) 2003-03-26
JP2002527525A (ja) 2002-08-27
DE69907495T2 (de) 2004-05-06
KR20060071897A (ko) 2006-06-27
US20050245496A1 (en) 2005-11-03
CA2344686A1 (en) 2000-04-27
HK1039620B (zh) 2003-08-22
CZ298703B6 (cs) 2007-12-27
EP1121375B1 (en) 2003-05-02
ES2197677T3 (es) 2004-01-01
RU2220975C2 (ru) 2004-01-10
SK4932001A3 (en) 2001-12-03
NO20011664L (no) 2001-04-03
CA2344686C (en) 2009-04-28

Similar Documents

Publication Publication Date Title
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
EP1100368A4 (en) SIGMIDOSKOP
PL345205A1 (en) New 3-aryl-2-hydroxypropionic acid derivative (i)
AP2000001874A0 (en) Cellecoxib compositions
GR3036646T3 (en) Formulations containing oxaliplatin
ZA986588B (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
PL342542A1 (en) Substituted 2-phenyl-1-(3,4-diphydroxy-5-nitrophenyl)-ethanones
AU4828799A (en) Pliers (2)
GB0014805D0 (en) Glassbreaker (2)
IL141850A (en) High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-3n-20-yn-3-one
GB9826555D0 (en) Microemulsion compositions
GB2339693B (en) Anti-mollusc compositions
AU2964899A (en) 2,4-dioxo-5-arylidenimino-1,3-pyrimidines
GB9800912D0 (en) New composition
HU9502822D0 (en) Compositions containing difluormethoxi-2,2,2-trifluor-ethane
GB0016470D0 (en) Compositions
GB2336535B (en) Compositions
HUP0100841A3 (en) Glycosidation of 4,5-epoxymorphinan-6-ols
AUPP003297A0 (en) 4,5-diaryloxazole compounds
AU1110699A (en) Estra-1,3,5(10)-triene-7alpha-thioethers
AU2645199A (en) Dialkyl-1-aryl-1-(2,4-dioxo-5-amino-1,3-pyrimidin-5-yl)methy lphosphonates
AU2115499A (en) 1,1,1,3,3-pentafluoropropane compositions
AU4263999A (en) Substituted 1,3-diaza-2-(thi)oxo-cycloalkanes
GB9815537D0 (en) 2,6-Quinolines
GB9828708D0 (en) Bis-terpyridine-platinum(11)complexes

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees